Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
1.420
-0.170 (-10.69%)
Mar 31, 2025, 1:31 PM EDT - Market open
Precigen Employees
Precigen had 143 employees as of December 31, 2024. The number of employees decreased by 59 or -29.21% compared to the previous year.
Employees
143
Change (1Y)
-59
Growth (1Y)
-29.21%
Revenue / Employee
$27,448
Profits / Employee
-$882,762
Market Cap
417.57M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PGEN News
- 11 days ago - Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Precigen Reports Full Year 2024 Financial Results and Business Updates - PRNewsWire
- 18 days ago - Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th - PRNewsWire
- 4 weeks ago - Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement - Seeking Alpha
- 4 weeks ago - FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 - PRNewsWire
- 2 months ago - Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 3 months ago - Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis - PRNewsWire